2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial Dr.

Slides:

Advertisements

Similar presentations

Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas Featured Article: Boris P. Kovatchev, Eric.

Advertisements

Feasibility of Outpatient Fully Integrated Closed-Loop Control First studies of wearable artificial pancreas Featured Article: Boris P. Kovatchev, Ph.D.,

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Volume 379, Issue 9824, Pages (April 2012)

Volume 384, Issue 9961, Pages (December 2014)

Volume 17, Issue 12, Pages (December 2016)

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive.

Volume 367, Issue 9517, Pages (April 2006)

Volume 357, Issue 9257, Pages (March 2001)

Volume 370, Issue 9601, Pages (November 2007)

Volume 359, Issue 9322, Pages (June 2002)

Pharmacogenetics and future drug development and delivery

Volume 11, Issue 4, Pages (April 2012)

Volume 376, Issue 9734, Pages (July 2010)

Thank God for Richard Dawkins?

Volume 372, Issue 9633, Pages (July 2008)

Total and cause-specific mortality before and after the onset of the Greek economic crisis: an interrupted time-series analysis Ioannis Laliotis, PhD,

Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study

Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled.

Volume 379, Issue 9824, Pages (April 2012)

Gian Paolo Fadini, Angelo Avogaro The Lancet Diabetes & Endocrinology

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Abdominal lipohypertrophy without insulin injection

Volume 371, Issue 9611, Pages (February 2008)

Volume 376, Issue 9734, Pages (July 2010)

Volume 13, Issue 3, Pages (March 2012)

Volume 372, Issue 9633, Pages (July 2008)

Volume 366, Issue 9486, Pages (August 2005)

21st century diabetes care: a marriage between humans and technology

Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled.

Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel- group trial Hood Thabit, PhD, Sara Hartnell, BSc, Janet M Allen,

Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study

Volume 389, Issue 10071, Pages (February 2017)

Volume 373, Issue 9663, Pages (February 2009)

Volume 375, Issue 9716, Pages (February 2010)

Non-uraemic calciphylaxis with acral necrosis

Volume 372, Issue 9642, Pages (September 2008)

The Gobi Desert medical kit

Volume 2, Issue 6, Pages (June 2015)

Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort.

Volume 9, Issue 10, Pages (October 2008)

Can famine relief meet health and hunger goals simultaneously?

Volume 10, Issue 4, Pages (April 2011)

Volume 392, Issue 10141, Pages (July 2018)

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study Sune F Nielsen, PhD, Prof Børge G Nordestgaard,

Volume 375, Issue 9732, Pages (June 2010)

Volume 4, Issue 6, Pages (June 2017)

Volume 379, Issue 9821, Pages (March 2012)

Cold water immersion: sudden death and prolonged survival

Volume 382, Issue 9888, Pages (July 2013)

Volume 6, Issue 6, Pages (June 2005)

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled.

Volume 12, Issue 8, Pages (August 2013)

Volume 388, Issue 10058, Pages (November 2016)

Volume 372, Issue 9647, Pages (October 2008)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 371, Issue 9627, Pages (May 2008)

Thank God for Richard Dawkins?

The emotional journey of gestational diabetes

Volume 375, Issue 9714, Pages (February 2010)

Volume 361, Issue 9352, Pages (January 2003)

An unusual case of hypopituitarism

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial Dr David Preiss, PhD, Suzanne M Lloyd,

Volume 378, Issue 9802, Pages (October 2011)

Volume 372, Issue 9632, Pages (July 2008)

Volume 368, Issue 9541, Pages (September 2006)

Clinic attendance and disengagement of young adults with type 1 diabetes after transition of care from paediatric to adult services (TrACeD): a randomised,

Volume 371, Issue 9611, Pages (February 2008)

Reversible biological adaptations in obesity

A disease of the osteoblast

Presentation transcript:

2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial Dr Jort Kropff, MD, Simone Del Favero, PhD, Jerome Place, MSc, Chiara Toffanin, PhD, Roberto Visentin, MSc, Marco Monaro, MSc, Mirko Messori, MSc, Federico Di Palma, PhD, Giordano Lanzola, PhD, Anne Farret, MD, Federico Boscari, MD, Silvia Galasso, MD, Prof Paolo Magni, PhD, Prof Angelo Avogaro, MD, Patrick Keith-Hynes, PhD, Prof Boris P Kovatchev, PhD, Daniela Bruttomesso, MD, Prof Claudio Cobelli, PhD, J Hans DeVries, MD, Prof Eric Renard, MD, Prof Lalo Magni, PhD The Lancet Diabetes & Endocrinology Volume 3, Issue 12, Pages 939-947 (December 2015) DOI: 10.1016/S2213-8587(15)00335-6 Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile AP=artificial pancreas. The Lancet Diabetes & Endocrinology 2015 3, 939-947DOI: (10.1016/S2213-8587(15)00335-6) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 2 Percentage of time spent in and below target glucose concentration range for all study participants during 2000–0800 h Mean evening and night (2000–0800 h) percentage time in target range (3·9–10·0 mmol/L) is given for each patient for the control period, which is connected to the mean percentage time in target range for the AP period. The diameter of the circle shows percentage of time (either <1% or 5%) spent below the target range in either period. AP=artificial pancreas. The Lancet Diabetes & Endocrinology 2015 3, 939-947DOI: (10.1016/S2213-8587(15)00335-6) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 3 24 h glucose control profile The glucose control profile of all patients analysed is shown as superimposed continuous traces of glucose monitoring during the AP and control periods. Mean blood glucose is given with 1 SD. Purple shading represents the SD for the AP period and blue shading represents the SD for the control period. 3·9–10 mmol/L represents the target glucose concentration range and 4·4–7·8 mmol/L represents the tight glucose target. AP=artificial pancreas. The Lancet Diabetes & Endocrinology 2015 3, 939-947DOI: (10.1016/S2213-8587(15)00335-6) Copyright © 2015 Elsevier Ltd Terms and Conditions